Citigroup Maintains Buy on Nabors Industries, Lowers Price Target to $200
Citigroup analyst Scott Gruber maintains Nabors Industries (NYSE:NBR) with a Buy and lowers the price target from $210 to $200.
Where Nabors Industries Stands With Analysts
Nabors Industries (NYSE:NBR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Nabors Industries Raised $225M Via Private Senior Unsecured Note Offering For Debt Repayment
Nabors Industries Ltd. ("Nabors") (NYSE:NBR) announced today that its wholly owned subsidiary, Nabors Industries, Inc. ("NII"), has priced $225,000,000 in aggregate principal amount of
Susquehanna Maintains Neutral on Nabors Industries, Raises Price Target to $215
Susquehanna analyst Charles Minervino maintains Nabors Industries (NYSE:NBR) with a Neutral and raises the price target from $189 to $215.
Earnings Scheduled For February 7, 2023
Companies Reporting Before The Bell
• BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.
Benzinga’s Top Ratings Upgrades, Downgrades For January 10, 2023
Upgrades Morgan Stanley upgraded the previous rating for Stem Inc (NYSE:STEM) from Equal-Weight to Overweight. In the third…
Barclays Upgrades Nabors Industries to Overweight, Announces $200 Price Target
Barclays analyst Derek Podhaizer upgrades Nabors Industries (NYSE:NBR) from Equal-Weight to Overweight and announces $200 price target.
Analyst Ratings for Nabors Industries
Within the last quarter, Nabors Industries (NYSE:NBR) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Morgan Stanley Maintains Underweight on Nabors Industries, Raises Price Target to $175
Morgan Stanley analyst Connor Lynagh maintains Nabors Industries (NYSE:NBR) with a Underweight and raises the price target from $140 to $175.
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Gainers
Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash.